Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Maitongna** is Luye Pharma's marketed brand of **sodium aescinate for injection**, a plant-derived venotonic and anti-edema pharmaceutical used in China for **cerebral edema**, **swelling caused by trauma or surgery**, and **venous reflux disorders**. Sodium aescinate is a mixture of triterpenoid saponins derived from horse chestnut and is used clinically for anti-inflammatory, anti-exudative, capillary-protective, and venous tone-enhancing effects; reported pharmacology in Chinese labeling includes increased venous tone, promotion of venous blood flow and lymphatic return, improvement of microcirculation, and reduction of tissue edema. The product is marketed by Luye Pharma and appears to be supplied as an injectable formulation for intravenous use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Maitongna.